Drug Profile
HMR 1098
Alternative Names: 1098; Clamikalant sodiumLatest Information Update: 02 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis
- Class Antiarrhythmics; Benzamides; Small molecules
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias; Heart arrest
Most Recent Events
- 18 Jun 2002 Discontinued - Phase-II for Arrhythmias in USA (unspecified route)
- 18 Jun 2002 Discontinued - Phase-II for Heart arrest in USA (unspecified route)
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma